Evidence map›Paper›PMID 40434956›Full record

ArticleFuture oncology (London, England)2025

Busulfan-cyclophosphamide vs fludarabine-busulfan for allogeneic transplant in acute myeloid leukemia.

Ben Abdeljelil N, Kanoun R Y, Mekni S, Turki I, Ben Yaiche I, Ouerghi R, Belloumi D, Torjemane L, Ladeb S, Ben Othman T

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ben Abdeljelil NDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Kanoun R YDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Mekni SDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Turki IDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Ben Yaiche IDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Ouerghi RDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Belloumi DDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Torjemane LDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Ladeb SDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.
Ben Othman TDepartment of Hematology and Graft, National Bone Marrow Transplantation Center, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBusulfan and cyclophosphamide (BuCy) is the standard myeloablative conditioning regimen for patients with acute myeloblastic leukemia (AML) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Fludarabine and busulfan (FluBu) conditioning seems to have similar efficacy with less toxicity. AIMS AND

methodsDescriptive retrospective study conducted on patients with AML who underwent geno-identical allo-HSCT between January 2011 and December 2022. Patients received a myeloablative conditioning with either BuCy2 orFluBu4. The objective was to compare the efficacy and safety of this regimens.

resultsA total of 113 adult patients were included. Conditioning regimen was BuCy2 in 81% of patients (

conclusionMyeloablative FluBu4 conditioning appeared to achieve clinical outcomes similar to BuCy2 and may be considered as a possible alternative for patients at high risk of NRM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation ConditioningAdolescentAdultAgedBusulfanCyclophosphamideFemaleGraft vs Host DiseaseHumansMaleMiddle AgedRetrospective StudiesTransplantation, HomologousBusulfanCyclophosphamidefludarabineVidarabineAcute myeloid leukemiaallogeneic hematopoietic stem cell transplantationbusulfanconditioning regimenscyclophosphamidefludarabine

Identifiers

PMID40434956
PMCPMC12150614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.